Maintenance (MT) treatment (Tx) after lenalidomide, bortezomib, and dexamethasone (RVD) induction and stem cell transplant (SCT) in high-risk (HR) patients (pts) with newly diagnosed multiple myeloma (NDMM): A real-world analysis.

被引：1
|
作者：
Fonseca, Rafael
Parikh, Kejal
Ung, Brian
Ni, Quanhong
Agarwal, Amit
机构：
[1] Mayo Clin, Phoenix, AZ USA
[2] Celgene Corp, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e20041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20041
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT)
    Fonseca, Rafael
    Parikh, Kejal
    Ung, Brian
    Ni, Quanhong
    Abouzaid, Safiya
    Agarwal, Amit
    [J]. BLOOD, 2017, 130
  • [2] Effect of maintenance therapy (MT) on real-world outcomes (RWO) of patients (pts) with newly diagnosed multiple myeloma (NDMM) post stem cell transplant (SCT)
    Parmar, Harsh
    Barcellos, Anna
    Biran, Noa
    Phull, Pooja
    Vesole, David H.
    Belli, Andrew J.
    Fernandes, Laura L.
    Hansen, Eric
    Zettler, Christina
    Wang, Ching-Kun
    Goran, Stefanie
    Anderson, Courtney
    Doucette, Kimberley
    Gunning, Thomas S.
    Ip, Andrew
    Siegel, David Samuel DiCapua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sara A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Lutska, Yana
    Bobba, Padma
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter M.
    [J]. BLOOD, 2021, 138
  • [4] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
    Anderson, Larry D., Jr.
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Voorhees, Peter M.
    Richardson, Paul G.
    [J]. BLOOD, 2021, 138
  • [5] Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
    Joseph, Nisha S.
    Kaufman, Jonathan L.
    Dicamillo, Sara
    Roberts, Danielle
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Boise, Lawrence H.
    Lonial, Sagar
    Nooka, Ajay K.
    [J]. BLOOD, 2023, 142
  • [6] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
    Joseph, Nisha
    Kaufman, Jonathan
    Lonial, Sagar
    Hofmeister, Craig
    Dhodapkar, Madhav
    Gupta, Vikas
    DiCamillo, Sara
    Roberts, Danielle
    Boise, Lawrence
    Nooka, Ajay
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113
  • [7] Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment
    Saeed, Nabiha
    Khan, Zurrya
    Jehanzeb, Hamzah
    Shaikh, Taha
    Shaikh, Usman
    Adil, Salman N.
    Madni, Varisha
    Fatima, Hania
    Abiha, Umm E.
    Ali, Natasha
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [8] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sara A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Lutska, Yana
    Bobba, Padma
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter M.
    [J]. BLOOD, 2020, 136
  • [9] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Shune, Leyla
    Badros, Ashraf
    Chari, Ajai
    Richardson, Paul G.
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    Hoehn, Daniela
    Lin, Thomas S.
    Voorhees, Peter M.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S308 - S309
  • [10] Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM).
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Muppidi, Samatha
    Heffner, Leonard T.
    Gleason, Charise
    Boise, Lawrence
    Lonial, Sagar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345